500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
This extension study is designed to evaluate the long-term safety, tolerability and
efficacy of FTY720 in patients with multiple sclerosis.
Ages:20 - 57
Inclusion Criteria: - Patients with relapsing-remitting disease who completed the 24 month core study with or without 24 months on study drug. Exclusion Criteria: - Other chronic diseases and conditions: of the immune system, malignancies, macular edema, diabetes, respiratory, cardiovascular. - Active systemic bacterial, viral or fungal infections. - Nursing and pregnant women. Other protocol-defined inclusion/exclusion criteria may apply.
Sponsor: Novartis Pharmaceuticals
Phase: Phase 3
Trial ID: NCT00774670
Not Accepting Healthy Volunteers